Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2011 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00880191
First received: April 10, 2009
Last updated: February 5, 2011
Last verified: February 2011

April 10, 2009
February 5, 2011
April 2009
August 2011   (final data collection date for primary outcome measure)
  • Comparison of percentage of complete responders, with complete response being defined as no emetic episodes and no use of rescue therapy for days 2 through 6 [ Designated as safety issue: No ]
  • Complete response, defined as no emetic episodes, no more than a mean of 2.5 on the nausea numeric analogue scale, and no rescue agents [ Designated as safety issue: No ]
  • Comparison of percentages of complete responders on day 1, vs days 1 through 6 vs days 2 through 6 [ Designated as safety issue: No ]
  • Comparison of the proportion of patients experiencing emetic episodes and the proportion needing rescue agents [ Designated as safety issue: No ]
  • Toxicity [ Designated as safety issue: Yes ]
  • Comparison fo sum of the daily distress questions as well as the individual daily responses [ Designated as safety issue: No ]
  • Level of satisfaction for the control of nausea with the mean severity of nausea over the six days in the diary as well as the nausea subscale on the Functional Living Index - Emesis questionnaire [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00880191 on ClinicalTrials.gov Archive Site
Comparison of daily complete response endpoints [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy
Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Prevention of Delayed CINV (Chemotherapy Induced Nausea and Vomiting) in Patients Receiving Highly Emetogenic Chemotherapy

RATIONALE: Gabapentin may prevent or reduce delayed nausea and vomiting caused by chemotherapy. It is not yet known whether gabapentin is more effective than a placebo in preventing nausea and vomiting.

PURPOSE: This randomized phase III trial is studying the side effects of gabapentin and to see how well it works compared with a placebo in preventing nausea and vomiting in patients receiving chemotherapy.

OBJECTIVES:

  • To evaluate the effectiveness of gabapentin in controlling delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy as defined by the percentage of complete responders (no emetic episodes and no rescue medication) on days 2 through 6 (five days after receipt of highly emetogenic chemotherapy) compared to an effective prophylactic regimen.
  • To evaluate the effectiveness of gabapentin in controlling delayed CINV in patients receiving highly emetogenic chemotherapy as defined by the percentage of complete responders (no emetic episodes, no more than mild nausea, and no rescue medication) on days 2 through 6 compared to an effective prophylactic regimen.
  • To compare the effectiveness of these regimens in controlling acute CINV on day 1 of treatment in these patients.
  • To compare the use of rescue agents in these patients.
  • To determine the tolerability of gabapentin in these patients.
  • To evaluate the effect of gabapentin for delayed chemotherapy-induced nausea and vomiting on symptom distress and functional abilities in these patients.
  • To compare alternative endpoints and methods for assessing nausea and vomiting and to determine how these measures compare to patient's satisfaction with symptom control, distress and function.

OUTLINE: This is a multicenter study. Patients are stratified according to gender, age (< 50 years vs > 50 years), history of alcoholism (yes vs no), and history of motion sickness or history of pregnancy induced nausea/vomiting (yes vs no). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive oral dexamethasone with 5HT3 receptor antagonist and oral gabapentin once daily on day 1 of chemotherapy. Patients then receive oral dexamethasone twice daily with or without 5HT3 receptor antagonist on days 2-4, and oral gabapentin either two or three times daily on days 2-5 of chemotherapy.
  • Arm II: Patients receive oral dexamethasone with 5HT3 receptor antagonist and oral placebo once daily on day 1 of chemotherapy. Patients then receive oral dexamethasone twice daily with or without 5HT3 receptor antagonist on days 2-4, and oral placebo either two or three times daily on days 2-5 of chemotherapy.

Patients complete a Functional Living Index - Emesis questionnaire, an overall satisfaction survey, and a side effect experience diary at baseline and on day 6. Patients also complete a nausea and vomiting diary at baseline and periodically during study therapy.

Interventional
Phase 3
Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Supportive Care
  • Nausea and Vomiting
  • Unspecified Adult Solid Tumor, Protocol Specific
  • Drug: dexamethasone
    Given orally
  • Drug: gabapentin
    Given orally
  • Other: placebo
    Given orally
  • Experimental: Arm I
    Patients receive oral dexamethasone with 5HT3 receptor antagonist and oral gabapentin once daily on day 1 of chemotherapy. Patients then receive oral dexamethasone twice daily with or without 5HT3 receptor antagonist on days 2-4, and oral gabapentin either two or three times daily on days 2-5 of chemotherapy.
    Interventions:
    • Drug: dexamethasone
    • Drug: gabapentin
  • Experimental: Arm II
    Patients receive oral dexamethasone with 5HT3 receptor antagonist and oral placebo once daily on day 1 of chemotherapy. Patients then receive oral dexamethasone twice daily with or without 5HT3 receptor antagonist on days 2-4, and oral placebo either two or three times daily on days 2-5 of chemotherapy.
    Interventions:
    • Drug: dexamethasone
    • Other: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
416
Not Provided
August 2011   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Scheduled to receive highly emetogenic chemotherapy

    • May be scheduled to receive prophylactic treatment for acute nausea and vomiting with a 5HT3 antagonist and dexamethasone 20 mg on day 1 of chemotherapy treatment
    • May be scheduled to receive multiple day chemotherapy regimens as long as the chemotherapy drugs given on the subsequent days have mild or no emetogenic potential
  • Chemotherapy schedules must allow at least 7 days rest between courses involving administration of highly emetogenic chemotherapy
  • No primary CNS malignancy and/or CNS metastasis

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-2
  • Life expectancy ≥ 3 months
  • Creatinine ≤ 1.5 times upper limit of normal within the past 30 days
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Ability to complete questionnaire(s) by his/herself or with assistance
  • Able to swallow pills
  • No epilepsy or seizure history
  • No gastrointestinal obstruction, active peptic ulcer disease, or uncontrolled heartburn
  • No history of nausea and/or vomiting related to any kind of chemotherapy
  • No nausea or vomiting within the past 3 days
  • No history of allergic or other adverse reaction to gabapentin or pregabalin

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No prior moderate or highly emetogenic chemotherapy
  • No prior or concurrent aprepitant or any other NK-1 receptor antagonist
  • At least 1 months since prior and no concurrent gabapentin, pregabalin, or other anticonvulsants
  • At least 7 days since prior and no concurrent pelvic or abdominal radiotherapy
  • At least 3 days since prior antiemetics
  • No concurrent or planned use of lorazepam, diphenhydramine, eszopiclone, and/or dronabinol during the 6 days of this study, except for treatment of breakthrough nausea and vomiting
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00880191
CDR0000634077, NCCTG-N08C3
Not Provided
Not Provided
North Central Cancer Treatment Group
National Cancer Institute (NCI)
Principal Investigator: Debra Barton, RN, PhD, AOCN, FAAN Mayo Clinic
National Cancer Institute (NCI)
February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP